- Home
- GO vs ARVN Comparison
GO vs ARVN Comparison
Compare GO & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GO | ARVN |
|---|---|---|
| Founded | 1946 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Food Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.5M | 781.0M |
| IPO Year | 2019 | 2018 |
Fundamental Metrics
Financial Performance| Metric | GO | ARVN |
|---|---|---|
| Price | $6.88 | $10.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 10 | 20 |
| Target Price | $11.30 | ★ $15.35 |
| AVG Volume (30 Days) | ★ 4.0M | 837.2K |
| Earning Date | 05-05-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 58.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $4,688,759,000.00 | $262,600,000.00 |
| Revenue This Year | $2.48 | N/A |
| Revenue Next Year | $3.91 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $5.66 | $5.90 |
| 52 Week High | $19.41 | $14.22 |
Technical Indicators
Market Signals| Indicator | GO | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 44.82 | 42.64 |
| Support Level | $5.69 | $9.02 |
| Resistance Level | $7.29 | $14.03 |
| Average True Range (ATR) | 0.37 | 0.66 |
| MACD | 0.15 | 0.08 |
| Stochastic Oscillator | 67.83 | 40.59 |
Price Performance
Historical ComparisonAbout GO Grocery Outlet Holding Corp.
Grocery Outlet Holding Corp is a grocery store operator in the United States. It is a retailer of quality, name-brand consumables and fresh products sold through a network of independently operated stores. The stores are run by Entrepreneurial independent operators which create a neighborhood feel through personalized customer service and a localized product offering.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.